BACKGROUND: In 2017, the International Parkinson and Movement Disorder Society put forward new clinical criteria for the diagnosis of PSP, recognizing diverse PSP phenotypes. In this study, we compared the sensitivity and specificity of the new criteria with the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria at different times. METHODS: Patients with clinical parkinsonism, clinical and/or neuropathological diagnosis of PSP, were identified from the Society for Progressive Supranuclear Palsy brain bank. All patients had neuropathologic diagnoses and detailed clinical examination performed by a neurologist at 1 of the 3 Mayo Clinic sites, in Florida, Arizona, and Minnesota. Clinical symptoms and signs were abstracted retrospectively in a blinded fashion and used to determine whether patients met either diagnostic criterion. Patients were divided into early and late disease stage groups using a 3-year cutoff. RESULTS: A total of 129 patients were included, of whom 66 had PSP pathology (51%). The remainder had other neurodegenerative diseases. The overall sensitivity of the International Parkinson and Movement Disorder Society criteria was 87.9%, compared with 45.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria, whereas the specificity of the International Parkinson and Movement Disorder Society probable PSP criteria was 85.7%, compared with 90.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy. Individual patients were noted to have features of multiple PSP phenotypes. CONCLUSION: The International Parkinson and Movement Disorder Society criteria recognize several phenotypes of progressive supranuclear palsy and hence have higher sensitivity than the previous criteria.
BACKGROUND: In 2017, the International Parkinson and Movement Disorder Society put forward new clinical criteria for the diagnosis of PSP, recognizing diverse PSP phenotypes. In this study, we compared the sensitivity and specificity of the new criteria with the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria at different times. METHODS:Patients with clinical parkinsonism, clinical and/or neuropathological diagnosis of PSP, were identified from the Society for Progressive Supranuclear Palsy brain bank. All patients had neuropathologic diagnoses and detailed clinical examination performed by a neurologist at 1 of the 3 Mayo Clinic sites, in Florida, Arizona, and Minnesota. Clinical symptoms and signs were abstracted retrospectively in a blinded fashion and used to determine whether patients met either diagnostic criterion. Patients were divided into early and late disease stage groups using a 3-year cutoff. RESULTS: A total of 129 patients were included, of whom 66 had PSP pathology (51%). The remainder had other neurodegenerative diseases. The overall sensitivity of the International Parkinson and Movement Disorder Society criteria was 87.9%, compared with 45.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria, whereas the specificity of the International Parkinson and Movement Disorder Society probable PSP criteria was 85.7%, compared with 90.5% for the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy. Individual patients were noted to have features of multiple PSP phenotypes. CONCLUSION: The International Parkinson and Movement Disorder Society criteria recognize several phenotypes of progressive supranuclear palsy and hence have higher sensitivity than the previous criteria.
Authors: I Litvan; Y Agid; J Jankovic; C Goetz; J P Brandel; E C Lai; G Wenning; L D'Olhaberriague; M Verny; K R Chaudhuri; A McKee; K Jellinger; J J Bartko; C A Mangone; R K Pearce Journal: Neurology Date: 1996-04 Impact factor: 9.910
Authors: I Litvan; G Campbell; C A Mangone; M Verny; A McKee; K R Chaudhuri; K Jellinger; R K Pearce; L D'Olhaberriague Journal: Brain Date: 1997-01 Impact factor: 13.501
Authors: Hanna Cho; Jae Yong Choi; Mi Song Hwang; Seung Ha Lee; Young Hoon Ryu; Myung Sik Lee; Chul Hyoung Lyoo Journal: Mov Disord Date: 2016-11-03 Impact factor: 10.338
Authors: I Litvan; Y Agid; D Calne; G Campbell; B Dubois; R C Duvoisin; C G Goetz; L I Golbe; J Grafman; J H Growdon; M Hallett; J Jankovic; N P Quinn; E Tolosa; D S Zee Journal: Neurology Date: 1996-07 Impact factor: 9.910
Authors: J L Whitwell; C R Jack; J E Parisi; J L Gunter; S D Weigand; B F Boeve; J E Ahlskog; R C Petersen; D W Dickson; K A Josephs Journal: Eur J Neurol Date: 2013-06-07 Impact factor: 6.089
Authors: Jennifer L Whitwell; Val J Lowe; Nirubol Tosakulwong; Stephen D Weigand; Matthew L Senjem; Christopher G Schwarz; Anthony J Spychalla; Ronald C Petersen; Clifford R Jack; Keith A Josephs Journal: Mov Disord Date: 2016-10-27 Impact factor: 10.338
Authors: Jennifer L Whitwell; Günter U Höglinger; Angelo Antonini; Yvette Bordelon; Adam L Boxer; Carlo Colosimo; Thilo van Eimeren; Lawrence I Golbe; Jan Kassubek; Carolin Kurz; Irene Litvan; Alexander Pantelyat; Gil Rabinovici; Gesine Respondek; Axel Rominger; James B Rowe; Maria Stamelou; Keith A Josephs Journal: Mov Disord Date: 2017-05-13 Impact factor: 10.338
Authors: Günter U Höglinger; Gesine Respondek; Maria Stamelou; Carolin Kurz; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Christer Nilsson; Jennifer L Whitwell; Thomas Arzberger; Elisabet Englund; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Yaroslau Compta; Jean-Christophe Corvol; Carlo Colosimo; Dennis W Dickson; Richard Dodel; Leslie Ferguson; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw R Morris; Peter Nestor; Wolfgang H Oertel; Werner Poewe; Gil Rabinovici; James B Rowe; Gerard D Schellenberg; Klaus Seppi; Thilo van Eimeren; Gregor K Wenning; Adam L Boxer; Lawrence I Golbe; Irene Litvan Journal: Mov Disord Date: 2017-05-03 Impact factor: 10.338
Authors: Max-Joseph Grimm; Gesine Respondek; Maria Stamelou; Thomas Arzberger; Leslie Ferguson; Ellen Gelpi; Armin Giese; Murray Grossman; David J Irwin; Alexander Pantelyat; Alex Rajput; Sigrun Roeber; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Carlo Colosimo; Thilo van Eimeren; Jan Kassubek; Johannes Levin; Wassilios G Meissner; Christer Nilsson; Wolfgang H Oertel; Ines Piot; Werner Poewe; Gregor K Wenning; Adam Boxer; Lawrence I Golbe; Keith A Josephs; Irene Litvan; Huw R Morris; Jennifer L Whitwell; Yaroslau Compta; Jean-Christophe Corvol; Anthony E Lang; James B Rowe; Günter U Höglinger Journal: Mov Disord Date: 2019-03-18 Impact factor: 10.338
Authors: Gesine Respondek; Max-Joseph Grimm; Ines Piot; Thomas Arzberger; Yaroslau Compta; Elisabet Englund; Leslie W Ferguson; Ellen Gelpi; Sigrun Roeber; Armin Giese; Murray Grossman; David J Irwin; Wassilios G Meissner; Christer Nilsson; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Günter U Höglinger Journal: Mov Disord Date: 2019-09-30 Impact factor: 10.338
Authors: Ali Shoeibi; Irene Litvan; Jorge L Juncos; Yvette Bordelon; David Riley; David Standaert; Stephen G Reich; David Shprecher; Deborah Hall; Connie Marras; Benzi Kluger; Nahid Olfati; Joseph Jankovic Journal: Parkinsonism Relat Disord Date: 2019-10-14 Impact factor: 4.891
Authors: Rebecca R Valentino; Shunsuke Koga; Michael G Heckman; Danielle E Brushaber; Nancy N Diehl; Ronald L Walton; Dennis W Dickson; Owen A Ross Journal: Mov Disord Date: 2020-03-06 Impact factor: 10.338